---
title: "Bausch + Lomb makes progress on development of oral treatment for dry AMD"
section: market-watch
published: 2026-10-07T04:12:06.428009+00:00
canonical: https://valorandventures.media/article/321e00f0-837a-412d-b212-237ad206de99
publisher: "Valor & Ventures Media"
source: "Seeking Alpha"
source_url: https://seekingalpha.com/news/4650786-bausch-lomb-makes-progress-development-oral-treatment-dry-amd?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
access: free
---

# Bausch + Lomb makes progress on development of oral treatment for dry AMD

## Executive Summary

Bausch + Lomb, a prominent global eye health company, has achieved notable milestones regarding the development of its experimental oral therapeutic designed to treat dry age-related macular degeneration (dry AMD). According to a report from Seeking Alpha, the enterprise is steadily progressing in its clinical and developmental efforts to formulate a viable systemic treatment for this prevalent ocular condition. This announcement marks a potentially significant step forward for the pharmaceutical firm as it seeks to address a major unmet need in retinal health, where treatment options have historically been restricted or highly invasive. The pursuit of an oral medication for dry AMD represents a noteworthy shift in ophthalmic clinical research, which has frequently relied on localized therapies such as ocular injections. As Seeking Alpha reports, Bausch + Lomb's progress on an oral pipeline candidate signals a strategic attempt to simplify patient administration and expand treatment access. By focusing on a systemic, oral approach, the organization aims to bypass some of the clinical hurdles and patient discomfort associated with existing micro-injections, potentially altering the competitive landscape of the vision care sector. Developing treatments for dry AMD is widely recognized as one of the more formidable tasks in modern ophthalmology. Because the disease involves the gradual degradation of crucial retinal tissues, identifying therapeutic compounds that can safely halt or slow this progression through oral delivery is exceptionally complex. The report indicates that Bausch + Lomb’s ongoing research and development efforts reflect a broader industry push to leverage advanced biomedical science to deliver effective, non-invasive therapies to aging demographics globally. From an industry perspective, Bausch + Lomb's advancement of this program highlights the intense research and development competition within the biotechnology and pharmaceutical markets. Successfully navigating the clinical phases of drug development is a complex and capital-intensive endeavor, requiring rigorous scientific validation and regulatory oversight. For market analysts and industry observers, updates on this pipeline serve as a critical indicator of the company’s long-term growth trajectory and its capacity to capture market share in high-value therapeutic categories. For the leaders, founders, and executives in the Valor & Ventures Media community, this development illustrates the strategic importance of sustained innovation and portfolio diversification in mature industries. Developing breakthroughs in highly regulated fields like healthcare demands not only scientific excellence but also visionary leadership, long-term capital commitment, and robust risk management. As Bausch + Lomb continues to advance its oral candidate, the progression offers valuable insights into how established corporate entities can leverage specialized research initiatives to address complex societal health challenges while driving sustainable economic value.

## Article

---
Seeking Alpha

---

Originally published by Seeking Alpha: https://seekingalpha.com/news/4650786-bausch-lomb-makes-progress-development-oral-treatment-dry-amd?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news